Calcineurin determines toxic versus beneficial responses to α-synuclein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages

  Caraveo, Gabriela ^a,b   Auluck, Pavan K ^a,c,h   Whitesell, Luke ^a   Chung, Chee Yeun ^a   Baru, Valeriya ^a,b   Mosharov, Eugene V ^d   Yan, Xiaohui ^e   Ben Johny, Manu ^f   Soste, Martin ^g   Picotti, Paola ^g   Kim, Hanna ^e   Caldwell, Kim A ^e   Caldwell, Guy A ^e   Sulzer, David ^d   Yue, David T ^f   Lindquist, Susan ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF ALABAMA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ETH ZURICH   (Switzerland)

^h BIOGEN   (United States)

Author keywords

Crz1; Neuroinflammation; NFAT; Slm2; TORC2

Indexed keywords

ALPHA SYNUCLEIN; CALCINEURIN; CALCIUM; PHOSPHATASE; TACROLIMUS; CALCINEURIN INHIBITOR; CALCINEURIN PHOSPHATASE; CALMODULIN; NFATC4 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CALCIUM CELL LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG TOLERABILITY; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOLOGICAL MODEL; CALCIUM SIGNALING; CELL CULTURE; DIFFUSE LEWY BODY DISEASE; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOUSE; PARKINSON DISEASE; SACCHAROMYCES CEREVISIAE; TOXICITY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; CALCINEURIN; CALCINEURIN INHIBITORS; CALCIUM SIGNALING; CALMODULIN; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NEURONS; NFATC TRANSCRIPTION FACTORS; PARKINSON DISEASE; PHOSPHORIC MONOESTER HYDROLASES; RATS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TACROLIMUS;

EID: 84906671144     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413201111     Document Type: Article

References (66)

1. Wojda U, Salinska E, Kuznicki J (2008) Calcium ions in neuronal degeneration. IUBMB Life 60(9):575-590.
2. Adamczyk A, Strosznajder JB (2006) Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels. Neuroreport 17(18):1883-1886. (Pubitemid 46006291)
3. Danzer KM, et al. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27(34):9220-9232. (Pubitemid 47312071)
4. Martin ZS, et al. (2012) α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: Relevance to human synucleopathic diseases. J Neurochem 120(3):440-452.
5. Buttner S, et al. (2012) The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca2+ levels to alpha-synuclein toxicity in Parkinson's disease models. Cell Death Differ 20(3):465-77.
6. Hurley MJ, Brandon B, Gentleman SM, Dexter DT (2013) Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136(Pt 7):2077-2097.
7. Pasternak B, et al. (2012) Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 175(7):627-635.
8. Dryanovski DI, et al. (2013) Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci 33(24):10154-10164.
9. Chan CS, et al. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447(7148):1081-1086. (Pubitemid 47014425)
10. Kupsch A, et al. (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741(1-2):185-196. (Pubitemid 26426315)
11. Li H, Rao A, Hogan PG (2011) Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol 21(2):91-103.
12. Bonilla M, Cunningham KW (2002) Calcium release and influx in yeast: TRPC and VGCC rule another kingdom. Sci STKE 2002(127):pe17.
13. Graef IA, Chen F, Crabtree GR (2001) NFAT signaling in vertebrate development. Curr Opin Genet Dev 11(5):505-512. (Pubitemid 32800723)
14. Rusnak F, Mertz P (2000) Calcineurin: Form and function. Physiol Rev 80(4):1483-1521.
15. Auluck PK, Caraveo G, Lindquist S (2010) α-Synuclein: Membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 26:211-233.
16. Chung CY, et al. (2013) Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342(6161):983-987.
17. Tardiff DF, et al. (2013) Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science 342(6161):979-983.
18. Cooper AA, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785):324-328. (Pubitemid 44480951)
19. Gitler AD, et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 105(1):145-150.
20. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302(5651):1772-1775. (Pubitemid 37505742)
21. Guzman JN, et al. (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468(7324):696-700.
22. Su LJ, et al. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3(3-4):194-208.
23. Singleton AB, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302(5646):841. (Pubitemid 37339619)
24. 2+- dependent switching in a cal-modulin-IQ domain complex. Biochemistry 45(22):6987-6995.
25. 2+) channel connectivity with calmodulin. Nature 463(7283):968-972.
26. Geiser JR, van Tuinen D, Brockerhoff SE, Neff MM, Davis TN (1991) Can calmodulin function without binding calcium? Cell 65(6):949-959. (Pubitemid 121001683)
27. Irwin DJ, et al. (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587-598.
28. Polymeropoulos MH, et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047. (Pubitemid 27443610)
29. Breuder T, Hemenway CS, Movva NR, Cardenas ME, Heitman J (1994) Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. Proc Natl Acad Sci USA 91(12):5372-5376. (Pubitemid 24174329)
30. Hilioti Z, Cunningham KW (2003) The RCN family of calcineurin regulators. Biochem Biophys Res Commun 311(4):1089-1093. (Pubitemid 37393431)
31. Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13(4):136-142.
32. Cao S, Gelwix CC, Caldwell KA, Caldwell GA (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 25(15):3801-3812. (Pubitemid 40570413)
33. Harrington AJ, Yacoubian TA, Slone SR, Caldwell KA, Caldwell GA (2012) Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease. J Neurosci 32(6):2142-2153.
34. Lee JI, et al. (2003) The Caenorhabditis elegans homologue of Down syndrome critical region 1, RCN-1, inhibits multiple functions of the phosphatase calcineurin. J Mol Biol 328(1):147-156.
35. Piña FJ, et al. (2011) Hph1 and Hph2 are novel components of the Sec63/Sec62 posttranslational translocation complex that aid in vacuolar proton ATPase biogenesis. Eukaryot Cell 10(1):63-71.
36. Qureshi HY, Paudel HK (2011) Parkinsonian neurotoxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 286(7):5055-5068.
37. Fadri M, Daquinag A, Wang S, Xue T, Kunz J (2005) The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. Mol Biol Cell 16(4):1883-1900.
38. deHart AK, Schnell JD, Allen DA, Tsai JY, Hicke L (2003) Receptor internalization in yeast requires the Tor2-Rho1 signaling pathway. Mol Biol Cell 14(11):4676-4684.
39. Cyert MS (2003) Calcineurin signaling in Saccharomyces cerevisiae: How yeast go crazy in response to stress. Biochem Biophys Res Commun 311(4):1143-1150.
40. Picotti P, et al. (2010) High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 7(1):43-46.
41. Roy J, Li H, Hogan PG, Cyert MS (2007) A conserved docking site modulates substrate affinity for calcineurin, signaling output, and in vivo function. Mol Cell 25(6):889-901. (Pubitemid 46436530)
42. Liu Q, et al. (2012) Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae. ACS Chem Biol 7(6):982-987.
43. Aramburu J, et al. (1999) Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285(5436):2129-2133. (Pubitemid 29451431)
44. Stathopoulos AM, Cyert MS (1997) Calcineurin acts through the CRZ1/TCN1-encoded transcription factor to regulate gene expression in yeast. Genes Dev 11(24):3432-3444. (Pubitemid 28023965)
45. Doty RL (2012) Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 8(6):329-339.
46. Lin X, et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64(6):807-827.
47. Armstrong RA, et al. (2014) A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. J Neural Transm 121(2):171-181.
48. Chartier-Harlin MC, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440):1167-1169.
49. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J (1997) Neuroprotective actions of FK506 in experimental stroke: In vivo evidence against an antiexcitotoxic mechanism. J Neurosci 17(18):6939-6946. (Pubitemid 27427872)
50. Kitamura Y, Itano Y, Kubo T, Nomura Y (1994) Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 50(2):221-224. (Pubitemid 24071788)
51. Costantini LC, et al. (1998) A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol Dis 5(2):97-106. (Pubitemid 28430720)
52. Guo X, Dawson VL, Dawson TM (2001) Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 13(9):1683-1693. (Pubitemid 32488058)
53. Guo X, Dillman JF, 3rd, Dawson VL, Dawson TM (2001) Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Ann Neurol 50(1):6-16.
54. Armistead DM, et al. (1995) Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr D Biol Crystallogr 51(Pt 4):522-528.
55. Steiner JP, et al. (1997) Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med 3(4):421-428. (Pubitemid 27145684)
56. Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25(5):249-253. (Pubitemid 38553826)
57. Tadross MR, Ben Johny M, Yue DT (2010) Molecular endpoints of Ca2+/calmodulin- and voltage-dependent inactivation of Ca(v)1.3 channels. J Gen Physiol 135(3):197-215.
58. Dick IE, et al. (2008) A modular switch for spatial Ca2+ selectivity in the calmodulin regulation of CaV channels. Nature 451(7180):830-834. (Pubitemid 351253161)
59. Bean BP (2007) Neurophysiology: Stressful pacemaking. Nature 447(7148):1059-1060.
60. Martinez J, Moeller I, Erdjument-Bromage H, Tempst P, Lauring B (2003) Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J Biol Chem 278(19):17379-17387. (Pubitemid 36799623)
61. Lee D, Lee SY, Lee EN, Chang CS, Paik SR (2002) alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes. J Neurochem 82(5):1007-1017. (Pubitemid 34966613)
62. Mosharov EV, et al. (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62(2):218-229.
63. Thayanidhi N, et al. (2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell 21(11):1850-1863.
64. Nemani VM, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66-79.
65. Gitler AD, et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41(3):308-315.
66. Bodenmiller B, et al. (2010) Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal 3(153):rs4.